Company: PTPI
Filing Date: 2025-02-14
Form Type: S-1/A
Source: 0001410578-25-000137
Chunk: 89

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-1/A
Chunk 89
---
:----|:--------------------------|-------------:|
| Net loss                                     | ​ | $                         |  -5,045,350 | ​ | $           |  -5,137,132 | ​   | $                         |  -10,182,482 |
|                                              | ​ | ​                         |             | ​ | ​           |             | ​   | ​                         |              |
| Preferred Stock dividends and cash premiums  | ​ | ​                         |  -1,863,998 | ​ | ​           |             | ​   | ​                         |   -1,863,998 |
| Preferred Stock accretion                    | ​ | ​                         |  -9,099,230 | ​ | ​           |             | ​   | ​                         |   -9,099,230 |
|                                              | ​ | ​                         |             | ​ | ​           |             | ​   | ​                         |              |
| Net loss per common share                    | ​ | $                         | -16,008,578 | ​ | $           |  -5,137,132 | ​   | $                         |  -21,145,710 |
|                                              | ​ | ​                         |             | ​ | ​           |             | ​   | ​                         |              |
| Basic and Diluted                            | ​ | $                         |       -2.18 | ​ | ​           |             | ​   | $                         |        -2.88 |
| Weighted average common shares outstanding   | ​ | ​                         |             | ​ | ​           |             | ​   | ​                         |              |
| Basic                                        | ​ | ​                         |   7,332,030 | ​ | ​           |             | ​   | ​                         |    7,332,030 |
| Effects of common share equivalents          | ​ | ​                         |           — | ​ | ​           |             | ​   | ​                         |            — |
| Diluted                                      | ​ | ​                         |   7,332,030 | ​ | ​           |             | ​   | ​                         |    7,332,030 |

| (g) | The difference between the inventory and API value of $7.1 million and the collateral value of $2.0 million was treated as a loss on settlement with Vivus. |

50

### DESCRIPTION OF CAPITAL STOCK

#### General
The following description of our capital stock and provisions of our amended and restated certificate of incorporation (the “